{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"11.8","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Dexamethasone: Given PO Ixazomib Citrate: Given PO Laboratory Biomarker Analysis: Correlative studies Pomalidomide: Given PO","id":"OG000","title":"Treatment (Ixazomib Citrate, Pomalidomide, Dexamethasone)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"4 years 8 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}